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Ulcerative colitis (UC) is chronic remitting relapsing disease of gastrointestinal tract which 
together with Crohn’s disease (CD) is often grouped as inflammatory bowel disease (IBD). 
For a long time, all diarrhoeal diseases were believed to be caused by infectious agents such 
as bacteria. In 1875  Wilks and Moxon for the first time described UC as a separate entity 
different from infectious colitis [1]. Later in 1960, formal criteria to differentiate UC from CD 
were established. UC has an annual incidence of 10-20 per 100,000 compared to 5-10 per 
100,000 for CD, however these data are generally considered to be an underestimate [2, 3]. It 
predominantly affects younger population with a peak incidence between ages 20-40 yrs, 
however they may affect any age group; and up to 15% of individuals are above 60 yrs of 
age at the time of diagnosis. Currently IBD is estimated to affect as many as 1.4 million 
people in the United States and 2.2 millions in Europe [3]. UC usually causes continuous 
mucosal inflammation and is confined to the large bowel, except in a minority of patients 
where involvement extends to the terminal ileum, called “backwash ileitis”. Bloody diarrhoea, 
abdominal pain and passage of rectal mucous and blood are the predominant presenting 
symptoms of UC. In addition, extra-intestinal manifestations are also prevalent in UC 
although less common than CD; the most common being rheumatological (ankylosing 
spondylitis, axial arthritis), dermatological (erythema nodosum, pyoderma gangrenosum), 
and ophthalmological (scleritis, episcleritis) [4]. A small subgroup of patients (approximately 
10%) have disease affecting colon with histological features of both CD and UC which is 
termed as indeterminate colitis [5]. 
2. Epidemiology 
Epidemiological studies have revealed gender-related differences in UC with a slight 
predominance of males. It is traditionally considered to be most common in Western 
countries and least common in Asian pacific region, however its low incidence in the later is 
considered to be due to under-diagnosis and its overlap with infective diarrhoea [6]. The 
incidence of UC has increased markedly in the West since 1950s. The increase in the 
incidence of UC precedes that of CD by about 15-20 years [7]. Geographically, the 
prevalence of the disease has a gradient from North to South and, to a lesser degree, from 
West to East. The Western-Eastern discrepancy can be attributed to urbanization and a 
difference in Western lifestyles [8]. 
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The incidence of the disease has been increasing worldwide of late, but the rate of  increase 
has been slowing in highly affected countries [9]. Racial and ethnic observations in different 
populations reflect genetic, inherited, environmental and behavioural factors. The disease 
seems to have a characteristic racial-ethnic distribution: blacks are less affected by the UC 
than whites and the Jewish population is highly susceptible to both UC and CD  
everywhere, but its prevalence in a particular population nears that of the domestic 
society in which they live [10]. A study from northern England suggested that the 
prevalence of UC in 1995 was as high as 243 cases per 100,000 persons [2]. Recent data 
from Cardiff, UK showed that incidence of CD continue to rise slowly with female 
preponderance [11], and a similar trend has been seen in juvenile onset CD and UC in 
Scotland [12]. 
3. Aetiology 
Despite progress in our understanding of its immunopathogenesis, the exact aetiology of 
UC remains elusive and appears to be polygenic and multifactorial. It is postulated that 
there is chronic activation of immune and inflammatory cascade in genetically susceptible 
individual. Environmental factors play a significant role in the disease manifestation, course 
and prognosis of UC. A rapid increase in its incidence in developed countries, the 
occurrence of UC in spouses and a lack of complete concordance in monozygotic twins are 
strong arguments for the role of environmental factors in UC. Observations on temporal 
trends and geographical distribution point to risk factors associated with a Western lifestyle. 
Many studies have specifically looked for involvement of factors such as diet, smoking, and 
several infectious agents but, so far, only smoking cessation can be considered established 
risk factors for the manifestation of the disease [13]. A strong negative association between 
appendectomy and UC has been found consistently across many studies; however, the 
implications of this finding are still obscure [14]. 
Interaction of these various factors (environmental, microbial and immunological) 
contributes to the development of chronic intestinal inflammation in a genetically susceptible 
host. Genetic susceptibility is influenced by the luminal microbiota, which provides antigens 
and adjuvant that stimulate either pathogenic or protective immune responses. 
The gut microbiota has been known to be involved in the induction and perpetuation of 
immune-mediated bowel inflammation for a long time and the most revealing evidence for 
its potential involvement came from the study of genetically engineered mice in which 
colitis did not develop if mice were kept in a germ-free environment [15],[16]. More 
importantly, UC preferentially occurs in the colon which contains the highest intestinal 
bacterial concentrations. Moreover, the composition and function of microbiota in UC, and 
pouchitis are abnormal. Such evidence points towards a strong association between mucosal 
microbiota and the development of CD. However, few investigators have examined in 
depth the involvement of disturbed intestinal microbiota composition in the pathogenesis 
of IBD. This is due to the difficulty in culturing relevant bacteria by conventional means. 
Over half of the intestinal bacteria are almost impossible to culture; their characterisation 
requires complex, labour-intensive, and time-consuming methods [17]. Furthermore, 
identifying bacterial strains can be inaccurate and determining the strain abundance can 
be difficult.  
More recently, the development of advanced molecular techniques has shown a breakdown 






decreased concentration of protective bacteria that produce short chain fatty acid (SCFA) 
such as butyrate can enhance mucosal permeability. Conversely, increased concentration of 
harmful bacteria might increases the production of toxic metabolites such as hydrogen 
sulfide that increase mucosal permeability and block butyrate metabolism. The increase in 
mucosal permeability may lead to activation of pathogenic T cell mediated and innate 
immune response through exposure of bacterial TLR ligands and antigen [20].  
 
 
Fig. 1. Possible etiological mechanisms for the development of IBD 
Altered composition of gut microbiota has been demonstrated by many studies both in CD 
and UC and also in pouchitis [21]. There is an increase in gut Enterobacteria mainly E. Coli 
[22], [23] and decrease in the Firmicutes in IBD, although no fundamental difference 
between CD and UC was found [22],[24]  some studies demonstrated microbial difference in 
active and inactive disease [23], [25].    
Other possible mechanisms by which gut microbiota can play a role in immune mediated 
intestinal injury are; functional alteration in commensal bacteria (such as increased epithelial 
adherence, mucosal invasion, and resistant to killing) [26], defective containment of 
commensal bacteria where by defective killing of phagocytosed bacterial and ineffective 
clearance of bacterial antigen provide a persistent source of mucosal immune stimulation 
[27] and exaggerated mucosal immune response to commensal bacteria due to 
discoordinated homeostatic mechanism in intestinal epithelial cells [28] . 
4. Diagnosis 
Diagnosis of UC is based on clinical assessment followed by a combination of biochemical, 
endoscopic, radiological, histological, or nuclear medicine based investigations. Endoscopy 
with histology is considered to be the so called “gold standard” diagnostic modality 
History: Important aspects in history of patients with UC are duration and severity of 
symptoms, recent travel, medication, smoking, family history, stool frequency and 
consistency, urgency, rectal bleeding, abdominal pain, malaise, fever, weight loss, and 
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symptoms of extra-intestinal manifestations. Majority of patients presents with diarrhoea 
with or without blood, urgency abdominal pain, rectal bleed and systemic illness. The 
pattern of symptoms is usually depends on the extent of bowel involvement. For example, 
patients with pan-colitis are usually systemically ill and present with abdominal pain and 
bloody diarrhoea compared to those with limited colitis who remains systemically well 
despite similar symptoms of bloody diarrhoea.  
Examination: Examination findings may suggest the severity of disease and extent of 
involvement.  For example, patient with limited colitis and mild disease may have no 
specific clinical findings on examination and will be systemically well as compared to those 
with severe disease who may be systemically unwell, hypotensive,  tachycardic and may 
have generalised abdominal tenderness on examination. 
Investigation: Initial laboratory workup includes full blood count (FBC), U&Es, liver 
function tests, and erythrocyte sedimentation rate (ESR) or C reactive protein (CRP), and 
microbiological testing for infectious diarrhoea including Clostridium difficile toxin. 
Abdominal radiography is also important in patients with suspected severe UC. 
Endoscopic investigation: A flexible sigmoidoscopy should be performed to confirm the 
diagnosis. It enables taking biopsies for histology and also helps excluding other causes for 
diarrhoea such as infective, ischemic or CMV colitis.  Endoscopic changes characteristically 
extend in continuous fashion from anal verge to proximal colon. Full colonoscopy in acute 
severe colitis is not recommended as high risks of complications.  
Radiological investigations: A plan radiograph should be performed on admission to 
estimate the extent of disease and also to exclude colonic dilatation. Certain features on 
abdominal radiograph such as presence of mucosal islands or more than two gas-filled 
loops of small bowel may suggest severity of the disease and may predict poor response to 
medical treatment [29].  
Generally large bowel radiology is inferior to endoscopy in the diagnosic evaluation of UC 
but double contrast barium enemas; CT or MRI (with or without contrast) may have a place 
where endoscopy is contraindicated or unsuitable. Ultrasound scanning is very sensitive for 
thickened bowel wall in slimmer patients. Capsule endoscopy and white cell scanning lack 
sensitivity and specificity.  
Depending upon the extent of bowel involvement, the disease can be categorized as 
follows: 
• Proctitis: Where disease is limited to the rectum only  
• Left sided: disease involvement limited to the proportion of the colon distal to the 
splenic flexure  
• Extensive Colitis: Where bowel involvement extend proximal to the splenic flexure 
including Pancolitis 
Majority of patients have long standing diarrhoea before the diagnosis of UC is eventually 
made.  
The main differential is infective colitis, ischemic colitis, CMV colitis and drug induced 
colitis.  
5. Management 
Management is usually depends upon the severity, complexity and extent of disease. No 
treatment is an option in case of very mild and limited disease. In this section, we discuss in 






5.1 Management of severe colitis 
Acute severe colitis is a serious and life threatening emergency and in about 10% of all 
newly diagnosed cases, the first presentation is with acute severe colitis. Early recognition 
and prompt start of treatment is vital to the successful management and prevention of 
complications. Prior to the discovery of steroids in 1955 the mortality of acute severe UC 
was described to be as high as 33% in some studies and 75% in other study [30]. Early use of 
intravenous steroids has reduced the mortality to 7 % and even <1% in specialized centre 
[31]. 
Several criteria are in use to define severe colitis. One of the simple and most commonly 
used criteria is proposed by Truelove and Witts as shown in the table 1. 
 
 Mild UC Moderate Severe 
Bloody stool / day < 4 4-6 > 6 
Pulse < 90 90 - 100 > 100 
Temp < 37.5°C ≤ 37.8 °C >37.8 °C 
Hb >11.5g/dl > 10.5g/dl < 10.5 g/dl 
ESR < 20mm /h < 30 mm/h > 30 mm/h 
CRP Normal < 30mg/L > 30 mg/L 
Albumin Normal 30 - 35 < 30 
Table 1. Truelove & Witts criteria for severity of UC [32] 
A thorough clinical assessment is important to identify patients at risks and immediate 
admission to hospital is warranted for all those fulfilling the Truelove and Witts’ criteria for 
severe colitis [32] . Differential diagnosis for these patients will include infective, ischaemic, 
drug-induced and other inflammatory causes of colitis. Routine lab investigation such as full 
blood count, electrolyte and liver function tests and inflammatory markers along with plain 
abdominal radiograph should be carried out and a faecal specimen should be sent to 
exclude infective causes including C-Difficile. If the mucosa on a plain abdominal 
radiograph is unremarkable, a sensible approach is to treat decisively with corticosteroids, 
review the patient within a few days and admit for intensive treatment if there is no 
improvement.  Early sigmoidoscopy and biopsy should be performed as part of the initial 
assessment of the patient. Biopsies confirm the severity of the inflammation and allow other 
diagnoses such as cytomegalovirus (CMV), indicated by viral inclusion bodies, to be 
excluded. CMV colitis can mimic UC and is thought to be responsible for treatment failure 
in up to 10% of patients labelled as steroid-refractory. Treatment of CMV may obviate 
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colectomy. Care should be taken to monitor and correct electrolytes on a daily basis as 
almost every patient with severe colitis becomes hypokalaemic during intensive treatment 
as a result of loss through bowel in the form of diarrhoea and also intensive therapy with 
steroids contribute to the development of hypokalaemia. Since acute UC is associated with 
higher risk of venous thromboembolism, unfractionated heparin should be administered for 
prophylaxis purposes.  
5.2 Corticosteroids 
Steroids remain the treatment of choice in severe UC and usually given as intravenous 
Hydrocortisone 100mg four times a day. Early use of IV steroids has shown a significant 
reduction in mortality and therefore, should not be delayed whilst awaiting microbiological 
results for possible infective causes. IV treatment is best given for about 5 days while 
monitoring parameters for response objectively and on satisfactory response to IV steroids; 
oral Prednisolone can be instituted at 40 mg daily dose and tapered down gradually. It is 
important to attain a full remission before beginning tapering of steroids or rapid recurrence 
of symptoms may ensue [33].  
Approximately 60% of patients will only show partial response to corticosteroids which can 
be predicted through objective measures such as lack of clinical improvement and persistent 
raised inflammatory markers [34]. At presentation, low albumin, high CRP, short duration 
of illness and prior steroid use all portend an increased risk of medical failure. In an analysis 
of 189 patients with acute severe UC,  a stool frequency >9 in the first 24 h, an albumin <30 
g/l or a pulse rate >90 beats per minute after 24 hours of IV steroid was predictive of a 62% 
failure rate to steroids. Similarly in another prospective study, a stool frequency > 8/day or 
CRP > 45 mg/l on day 3 of intensive therapy were predictive of the need for colectomy in 
85% during that admission [35]. In case of failure of treatment with IV steroids, early use 
of Ciclosporin or Infliximab is now considered a rescue therapy in order to prevent 
colectomy.  
5.3 Ciclosporin 
Ciclosporin is a calcineurin inhibitor and prevents a cascade of downstream events that are 
necessary for T-cell activation and proliferation.  
It is used in an attempt to prevent surgery when intravenous corticosteroids have failed to 
induce a response [36] or in those with contraindication or intolerance of steroids due to 
psychoses, severe osteoporosis, uncontrolled diabetes or patient preference . It is usually 
started after steroid failure preferable on day 3 when little or no response is seen with IV 
steroids, and is converted to oral cyclosporine 5 mg/kg once a response has occurred. Oral 
ciclosporin is then generally continued for about 3 months, and azathioprine or 
mercaptopurine (6-MP) introduced to maintain remission once the steroid dose tapers 
below 20 mg/day. 
5.4 Infliximab 
Infliximab is a monoclonal antibody to tumour necrosis factor-α (TNFα) and is established 
treatment in active CD. In cases of UC, there are only few small trials which have shown its 
use in case of steroid failure. The recently published Active Ulcerative Colitis Trials (ACTs) 






steroids or thiopurines [37]. Infliximab has emerged a promising therapeutic option in 
circumstances where intravenous steroids show signs of failing. 
5-aminosalcylic acid (5-ASA) drugs are of little use during severe attacks of colitis and their 
role is usually reserved for maintenance of remission. Use of opioids and anticholinergic 
medication should be avoided during the acute attack in order to prevent development of 
megacolon, and NSAIDs should also be ceased.  
5.5 Surgery 
Surgical therapy requires a mutual decision by patient, surgeon and physician with 
consideration of optimum timing and remains a definitive procedure for the treatment of 
UC. Early involvement of an experienced colorectal surgical team with the 
gastroenterologist is crucial in decision-making. Close liaison with a stoma therapist is also 
necessary for continued education, support and postoperative follow-up.  
The most commonly performed procedure is a subtotal colectomy and ileostomy initially 
which later on followed by an elective completion proctectomy and the formation of an 
ileal-pouch anal anastomosis (IPAA). With timely surgery, a marked improvement in 
clinical condition is noted within a short span after colectomy. It improves quality of life, 
provide confidence and control in >90%, allow patients to stop immunomodulators and 
prevent the long-term risk of cancer. Most follow-up studies of patients undergoing IPAA 
report an average of six bowel motions per day, but up to 50% experience episodes of faecal 
leakage at some stage 
Surgery is associated with certain complications such as small bowel obstruction, 
anastomotic stricture, pouch leak and pelvic abscesses, and some late complications such as 
pouchitis. However, this has to be balanced against the poor outcome of medical therapy in 
patients who have had an episode of severe colitis.  
5.6 Management of Left sided UC 
The ECCO guidelines suggest that left sided UC with mild to moderate severity should be 
initially treated with combined oral and topical mesalazine therapy. Higher doses of 
mesalazine, usually a daily dose of 4.8gm is more effective than lower doses of 2.4 gm 
daily. The treatment does of topical mesalazine is usually 1gm daily and various studies 
have shown no additional benefits with higher topical doses. Treatment with systemic 
steroids is reserved for cases not responding to combined mesalazine therapy.  A usually 
starting dose of Prednisolone is 40mg daily for 2 weeks which is then tapered down by 5 
mg every week. Topical steroids are reserved for patients who are intolerant to topical 
mesalazine. 
5.7 Management of limited UC 
The preferred treatment for active proctitis is with topical therapy either with 5ASA based 
suppository or enema or steroid based enema. The usual daily dose of mesalazine 
suppositories is 1gm per day and is considered to be better in proctitis than enema. Various 
studies have shown topical mesalazine to be twice as effective as topical steroids in inducing 
remission. Therefore, mesalazine suppositories are recommended as first line treatment for 
active Proctitis while topical steroids are reserved for those who are less responsive or 
intolerant to topical mesalazine.  
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A significant proportion of patients with left sided UC or proctitis either remain refractory 
to treatment with 5ASA medication and steroids or are steroid dependant. Patients 
refractory to initial treatment would require more intensive treatment such as Infliximab, 
cyclosporine or Tacrolimus. Those who are steroid dependant would be a candidate for 
immunosuppressant and Azathioprin has shown better efficacy than mesalazine in inducing 
and maintaining remission in this groups of patient.  
A careful evaluation of patients who remain symptomatic despite initial treatment with 
mesalazine and or steroids is important and other causes such IBS and CMV colitis with a 
review of the diagnosis should be considered. Poor compliance with medication is another 
aspect which should be considered while dealing with treatment refractory patients.  
6. References 
[1] Wilks S Moxon W et al. Lectures on pathological anatomy (Lindsay and Blakiston, 
Philadelphia) 1875;2nd Edition:408-9. 
[2] G. P. Rubin et al. Inflammatory bowel disease: epidemiology and management in an 
English general practice population. Alimentary Pharmacology & Therapeutics 
2000;14:1553-9. 
[3] Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, 
and environmental influences. Gastroenterology 2004;126:1504-17. 
[4] Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel 
disease: Epidemiology, diagnosis, and management. Ann Med. 2010, 422:97-114. 
[5] Mitchell P, Rabau M, Haboubi N. Indeterminate colitis. Techniques in Coloproctology 
2007;11:91-6. 
[6] Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia–Pacific area: A 
comparison with developed countries and regional differences. Journal of Digestive 
Diseases;11:134-47. 
[7] Molinie F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn's 
disease and ulcerative colitis in Northern France (1988-1999). Gut 2004;53:843-8. 
[8] Shivananda S, Logan R, EC-IBD Study Group. Incidence of inflammatory disease across 
Europe: is there a difference between north and south? Gut 1996;39:690-7. 
[9] Loftus JEV, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, 
Minnesota, 1940-1993: Incidence, prevalence, and survival. Gastroenterology 
1998;114:1161-8. 
[10] Niv Y, Abuksis G, Fraser GM. Epidemiology of Crohn's disease in Israel: a survey of 
Israeli kibbutz settlements. The American Journal of Gastroenterology 1999;94:2961-5. 
[11] S. Gunesh et al. The incidence of Crohn's disease in Cardiff over the last 75 years: an 
update for 1996-2005. Alimentary Pharmacology & Therapeutics 2008;27:211-9. 
[12] Armitage E, Hazel E.; Wilson, David C.; Ghosh, S.  Increasing incidence of both 
juvenile-onset Crohn's disease and ulcerative colitis in Scotland. European Journal of 
Gastroenterology & Hepatology 2001;13:1439-47. 
[13] van der Heide F, Dijkstra A, Weersma RK, et al. Effects of active and passive smoking 
on disease course of Crohn's disease and ulcerative colitis. Inflammatory Bowel 
Diseases 2009;15:1199-207. 
[14] Koutroubakis IE, Kouroumalis EA. Role of appendicitis and appendectomy in the 






[15] Sartor RB, Rath HC, Lichtman SN, et al. Animal models of intestinal and joint 
inflammation. Baillière's Clinical Rheumatology 1996;10:55-76. 
[16] Sartor RB. Therapeutic manipulation of enteric microflora in IBD: antibiotic, probiotic 
and prebiotic. Gastroenterology. 2004; 126(6): 1620-33. 
[17] Suau A, Bonnet R, Sutren M, et al. Direct Analysis of Genes Encoding 16S rRNA from 
Complex Communities Reveals Many Novel Molecular Species within the Human 
Gut.  1999:4799-807. 
[18] Takaishi H, Matsuki T, Nakazawa A, et al. Imbalance in intestinal microflora 
constitution could be involved in the pathogenesis of inflammatory bowel disease. 
Int J Med Microbiol 2008;298:463-72. 
[19] Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in 
inflammatory bowel disease. Inflamm Bowel Dis 2006;12:106-11. 
[20] Thomas C, Dirk H. Bacteria- and host-derived mechanisms to control intestinal 
epithelial cell homeostasis: Implications for chronic inflammation.  Inflamm Bowel 
Dis 2007, 13(9);1153-1164. 
[21] Bibiloni R, Mangold M, Madsen KL, et al. The bacteriology of biopsies differs between 
newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients.  J Med 
Microbiol. 2006, 55:1141-9. 
[22] Frank DN, St. Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization 
of microbial community imbalances in human inflammatory bowel diseases.  Proc 
Natl Acad Sci USA. 2007:13780-5. 
[23] Baumgart M, Dogan B, Rishniw M, et al. Culture independent analysis of ileal mucosa 
reveals a selective increase in invasive Escherichia coli of novel phylogeny relative 
to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 
2007;1:403-18. 
[24] Kotlowski R, Bernstein CN, Sepehri S, et al. High prevalence of Escherichia coli 
belonging to the B2+D phylogenetic group in inflammatory bowel disease.  Gut 
2007,56(5):669-75. 
[25] Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive 
Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 
2004;127:412-21. 
[26] Korzenik JR. Is Crohn's disease due to defective immunity? Gut.  2007,56(1):2-5. 
[27] Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. 
Nature 2007;448:427-34. 
[28] Sartor RB. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative 
colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:390-407. 
[29] Prantera C LR, Cerro P et al. The plain abdominal film accurately estimates the extent of 
activity in ulcerative colitis. J Clin Gastroenterol 1991;13:321-4. 
[30] Bulmer T et al. Ulcerative Colitis-A survey of ninety five cases. British Medical Journal 
1933;2:812-5. 
[31] Rice-Oxley JM et al. Ulcerative colitis: course and prognosis. Lancet 1950;1:663-6. 
[32] Truelove SC, Witts L. Cortisone in ulcerative colitis: final report on a therapeutic trial. 
British Medical Journal 1955;2:1041-8. 
[33] Rosenberg W, Jewell DP. High-dose methylprednisolone in the treatment of active 
ulcerative colitis. J Clin Gastroenterol 1990;12:40-1. 
www.intechopen.com
 
Ulcerative Colitis – Epidemiology, Pathogenesis and Complications 
 
12
[34 Hawthorne AB et al. The BSG IBD Clinical Trials Network. Outcome of inpatient 
management of severe ulcerative colitis. Gut 2002;16:50. 
[35] Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis.  
Gut. 1996, 38(6):905-10. 
[36] Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in Severe Ulcerative Colitis 
Refractory to Steroid Therapy.  N Engl J Med 1994; 330:1841-1845 
[37] Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for Induction and Maintenance 
Therapy for Ulcerative Colitis.  2005:2462-76. 
 
www.intechopen.com
Ulcerative Colitis - Epidemiology, Pathogenesis and Complications
Edited by Dr Mortimer O'Connor
ISBN 978-953-307-880-9
Hard cover, 280 pages
Publisher InTech
Published online 14, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is intended to act as an up-to-date reference point and knowledge developer for all readers
interested in the area of gastroenterology and in particular, Ulcerative Colitis. All authors of the chapters are
experts in their fields of publication, and deserve individual credit and praise for their contributions to the world
of Ulcerative Colitis. We hope that you will find this publication informative, stimulating, and a reference point
for the area of Ulcerative colitis as we move forward in our understanding of the field of medicine.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Iftikhar Ahmed and Zafar Niaz (2011). Ulcerative Colitis, Ulcerative Colitis - Epidemiology, Pathogenesis and
Complications, Dr Mortimer O'Connor (Ed.), ISBN: 978-953-307-880-9, InTech, Available from:
http://www.intechopen.com/books/ulcerative-colitis-epidemiology-pathogenesis-and-complications/ulcerative-
colitis
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
